Primary end point and its determination: The primary endpoint will be mean AF burden over 3 months as measured by the Medtronic Reveal LINQ ICM system. All patients are scheduled to remain in the study for 6 months. The FDA-approved Medtronic Reveal LINQ ICM system is able to continuously monitor the heart through a single-lead ECG and has a specific algorithm that detects AF by evaluating the irregularity of R-R intervals. The device is able to correctly classify AF in 96.1% of patients and correctly exclude AF in 97.4% of subjects. The device is able to monitor the heart for up to 3 years and is compatible with the Medtronic CareLink Network remote monitoring system. This system allows the treating physician to download device and diagnostic data through a secure network. Patients transmit data manually after the device indicates that one of the alert criteria have been met. The occurrence of symptoms with the AF episode will be recorded, but both asymptomatic and symptomatic AF will be included in the primary endpoint measurement of AF burden.